Copyright
©The Author(s) 2018.
World J Gastroenterol. May 28, 2018; 24(20): 2191-2202
Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2191
Published online May 28, 2018. doi: 10.3748/wjg.v24.i20.2191
Table 1 Algorithm for evaluation of histological activity
Piecemeal necrosis | + | Lobular necrosis | = | Histological activity score |
0 (none) | 0 (none or mild) | 0 (none) | ||
0 | 1 (moderate) | 1 (mild) | ||
0 | 2 (severe) | 2 (moderate) | ||
1 (mild) | 0, 1 | 1 | ||
1 | 2 | 2 | ||
2 (moderate) | 0, 1 | 2 | ||
2 | 2 | 3 (severe) | ||
3 (severe) | 0, 1, 2 | 3 |
Table 2 Fibrosis scoring
Description | Score |
No fibrosis | 0 |
Stellate enlargement of portal tract but without septa formation | 1 |
Enlargement of portal tract with rare septa formation | 2 |
Numerous septa without cirrhosis | 3 |
Cirrhosis | 4 |
Table 3 Clinical characteristics of patients enrolled in this study n (%)
Seronegative OCI patients (n = 103) | Seropositive CHC patients (n = 155) | P value | |
Gender | 0.664 | ||
Male | 58 (56.3) | 83 (53.5) | |
Female | 45 (43.7) | 72 (46.5) | |
Age (yr) | 52.16 ± 7.64 | 42.70 ± 9.15 | < 0.001 |
ALT (IU/L) | 61.13 ± 23.54 | 93.17 ± 55.39 | < 0.001 |
GGT | 56.31 ± 16.63 | 52.86 ± 15.69 | 0.093 |
BMI | 23.73 ± 2.38 | 24.12 ± 2.36 | 0.192 |
HOMA-IR | 2.39 ± 0.15 | 2.42 ± 0.18 | 0.219 |
Transfusion/surgery/tattoo history | 8 (7.8) | 26 (16.8) | 0.027 |
Family history of HCV infection | 29 (28.2) | 19 (12.3) | < 0.001 |
Intrahepatic HCV RNA (log10 IU/mL) | 3.19 ± 1.05 | 5.48 ± 1.49 | < 0.001 |
HCV genotype | 0.89 | ||
Genotype 1 | 66 (64.1) | 98 (63.2) | |
Non-genotype 1 | 37 (35.9) | 57 (36.8) | |
Fibrosis (Fibroscan) | 0.317 | ||
F0-1 | 65 (63.1) | 104 (67.1) | |
F2-4 | 38 (36.9) | 51 (32.9) | |
METAVIR activity score | 1.14 ± 0.34 | 1.69 ± 0.68 | < 0.001 |
METAVIR fibrosis score | 1.82 ± 0.98 | 1.87 ± 1.07 | 0.673 |
Table 4 IL-28B single nucleotide polymorphism rs12979860 and CXCL10 single nucleotide polymorphism G-201A, C-1513T in occult hepatitis C virus infection and chronic hepatitis C virus infection patients n (%)
Seronegative OCI patients (n=103) | Seropositive CHC patients (n=155) | P value | |
IL-28BSNP rs12979860 | |||
C/C | 97 (94.2%) | 128 (82.6%) | 0.009 |
Non-C/C | 6 (5.8%) | 27 (17.4%) | |
CXCL10 SNP rs1439490 (G-201A) | |||
G/G | 93 (90.4%) | 116 (74.8%) | 0.003 |
G/A | 9 (8.7%) | 35 (22.6%) | |
A/A | 1 (0.9%) | 4 (2.6%) | |
CXCL10 SNP rs1440802 (C-1513T) | |||
C/C | 26 (25.2%) | 40 (25.8%) | 0.733 |
C/T | 54 (52.4%) | 78 (50.3%) | |
T/T | 23 (22.4%) | 37 (23.9%) |
Table 5 CXCL10 single nucleotide polymorphism G-201A in occult hepatitis C virus infection and chronic hepatitis C virus infection patients with IL-28B rs12979860 C/C n (%)
Seronegative OCI patients (n = 97) | Seropositive CHC patients (n = 128) | P value | OR (95%CI) | |
G/G | 87 (89.7) | 95 (74.2) | 0.005 | 0.331 (0.154-0.711) |
Non-G/G (G/A + A/A) | 10 (10.3) | 33(25.8) |
Table 6 Intrahepatic hepatitis C virus RNA, CXCL10 mRNA, and METAVIR scores of 8 seronegative occult hepatitis C virus infection patients who underwent a second liver biopsy
Patient ID | CXCL10G-201A SNP | Intrahepatic HCV RNA (log10 IU/mL) | Relative liver CXCL10 mRNA | METAVIRnecroinflammation score | METAVIRfibrosis scores | ||||
Before | After | Before | After | Before | After | Before | After | ||
1 | G/G | 2.17 | (-) | 1.20 | 0.80 | 1 | 0 | 0 | 0 |
2 | G/G | 3.57 | (-) | 0.95 | 0.90 | 1 | 0 | 1 | 1 |
3 | G/G | 2.72 | (-) | 0.74 | 0.63 | 1 | 1 | 1 | 1 |
4 | G/G | 5.08 | (-) | 1.31 | 0.94 | 1 | 0 | 1 | 0 |
5 | G/G | 2.83 | (-) | 1.42 | 0.64 | 1 | 0 | 0 | 0 |
6 | G/G | 1.97 | (-) | 1.06 | 0.83 | 2 | 1 | 1 | 1 |
7 | G/G | 4.64 | (-) | 1.03 | 0.70 | 2 | 0 | 2 | 1 |
8 | G/G | 2.94 | (-) | 1.26 | 0.71 | 1 | 1 | 3 | 1 |
Table 7 Intrahepatic hepatitis C virus RNA, CXCL10 mRNA, and METAVIR scores of 5 seropositive chronic hepatitis C virus infection patients who underwent a second liver biopsy
Patient ID | CXCL10G-201A SNP | Intrahepatic HCV RNA (log10 IU/mL) | Relative Liver CXCL10 mRNA | METAVIRnecroinflammation score | METAVIRfibrosis scores | ||||
Before | After | Before | After | Before | After | Before | After | ||
1 | G/G | 6.18 | (-) | 1.93 | 0.93 | 1 | 0 | 2 | 1 |
2 | G/G | 3.9 | (-) | 1.80 | 0.90 | 2 | 1 | 1 | 1 |
3 | G/A | 7.74 | 1.94 | 2.78 | 1.30 | 2 | 1 | 3 | 2 |
4 | G/A | 7.38 | (-) | 2.39 | 1.24 | 2 | 1 | 2 | 2 |
5 | G/G | 5.51 | 1.38 | 1.31 | 1.12 | 1 | 1 | 2 | 1 |
Table 8 Logistic regression analysis of factors associated with seronegative occult occurrence of hepatitis C virus
Variable | Univariate analysis | Multivariate analysis | ||||
OR | 95%CI | P value | OR | 95%CI | P value | |
Age | 1.15 | 1.11-1.19 | < 0.001 | |||
Blood transfusion | 0.39 | 0.17-0.92 | 0.031 | |||
Family history of HCV | 3.66 | 1.85-7.25 | < 0.001 | |||
Intrahepatic HCV RNA level | 0.30 | 0.23-0.39 | < 0.001 | |||
IL-28B C/C | 0.29 | 0.12-0.74 | 0.009 | 0.28 | 0.11-0.71 | 0.008 |
CXCL10 G-201A G/G | 0.32 | 0.15-0.68 | 0.003 | 0.31 | 0.15-0.66 | 0.002 |
- Citation: Wang X, Wang S, Liu ZH, Qi WQ, Zhang Q, Zhang YG, Sun DR, Xu Y, Wang HG, Li ZX, Cong XL, Zhao P, Zhou CY, Wang JB. Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection. World J Gastroenterol 2018; 24(20): 2191-2202
- URL: https://www.wjgnet.com/1007-9327/full/v24/i20/2191.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i20.2191